EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR
mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Authors
Keywords
-
Journal
Thoracic Cancer
Volume 9, Issue 7, Pages 814-819
Publisher
Wiley
Online
2018-05-03
DOI
10.1111/1759-7714.12651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
- (2018) Wen-Zhao Zhong et al. LANCET ONCOLOGY
- Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2018) Sanjay Popat NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
- (2017) Baohui Han et al. LUNG CANCER
- Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma
- (2016) In-Ho Kim et al. ANNALS OF SURGICAL ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients
- (2013) Mark Ragusa et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
- (2012) Sandra P. D’Angelo et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
- (2010) Gillian Ellison et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started